Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere dysfunction is implicated in the generation of large‐scale genomic rearrangements that drive progression to malignancy. In this study we used high‐resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) an...

Detaylı Bibliyografya
Asıl Yazarlar:	Williams, J, Heppel, N, Britt-Compton, B, Grimstead, J, Jones, R, Tauro, S, Bowen, D, Knapper, S, Groves, M, Hills, R, Pepper, C, Baird, D, Fegan, C
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Wiley 2017

Benzer Materyaller

Telomere length is a critical determinant for survival in multiple myeloma
Yazar:: Hyatt, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Maintenance of telomere length in AML
Yazar:: Peter M. Lansdorp
Baskı/Yayın Bilgisi: (2017-11-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
Yazar:: Nadia El Menshawy, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Inherited predisposition to MDS/AML
Yazar:: Ana Rio Machin, ve diğerleri
Baskı/Yayın Bilgisi: (2018-06-01)

Telomerase activity and telomere length in AML-M3 patients
Yazar:: Hamidollah Ghaffari, ve diğerleri
Baskı/Yayın Bilgisi: (2009-04-01)

Telomerase activity and telomere length in AML-M3 patients
Yazar:: Hamidollah Ghaffari, ve diğerleri
Baskı/Yayın Bilgisi: (2009-06-01)

T cell memory revisited using single telomere length analysis
Yazar:: Laureline Roger, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
Yazar:: Barbara De Moerloose
Baskı/Yayın Bilgisi: (2023-12-01)

Gene expression profiling in MDS and AML: potential and future avenues.
Yazar:: Theilgaard-Mönch, K, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
Yazar:: Jensen O, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
Yazar:: Hoyle, C, ve diğerleri
Baskı/Yayın Bilgisi: (1989)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
Yazar:: Olga K. Weinberg, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
Yazar:: Goh, Chermaine Yu Zhen
Baskı/Yayın Bilgisi: (2021)

p53 biology and reactivation for improved therapy in MDS and AML
Yazar:: Joanna E. Zawacka
Baskı/Yayın Bilgisi: (2024-03-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
Yazar:: V. Sheth, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
Yazar:: A. G. Lema Fernandez, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

PERFORMANCE OF CYTOGENETIC TESTS IN AML AND MDS SAMPLES PROCESSED IN A REMOTE LABORATORY IN BRAZIL
Yazar:: A Amaro, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
Yazar:: Petra Bašová, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
Yazar:: Udit Bhaskar Bhatnagar, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
Yazar:: Azra Raza, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
Yazar:: Ana Rio-Machin, ve diğerleri
Baskı/Yayın Bilgisi: (2020-02-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
Yazar:: Christoforos K. Vaxevanis, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
Yazar:: YE Xiangjun, LU Xingguo
Baskı/Yayın Bilgisi: (2023-10-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
Yazar:: V. Van Oorschot, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
Yazar:: Hongjiao Li, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
Yazar:: Lixian Chang, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
Yazar:: Guancui Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
Yazar:: Barreyro, L, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Telomere length in myelodysplastic syndromes.
Yazar:: Boultwood, J, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
Yazar:: Anson Snow, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
Yazar:: Tarik Möröy, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
Yazar:: Zuzana Tothova, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

TELOMERE LENGTH AND ATHEROSCLEROSIS
Yazar:: O. M. Drapkina, ve diğerleri
Baskı/Yayın Bilgisi: (2016-09-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
Yazar:: T. Ueda, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
Yazar:: A. Shastri, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
Yazar:: Sandra Huber, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML
Yazar:: Laura Barreyro, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
Yazar:: Victoria V. Grunwald, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
Yazar:: Amer M. Zeidan, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
Yazar:: Tahsin Anwar, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)